The Multiple Myeloma Landscape

Emily BurkeBiologics, Cancer, Clinical Trials, Drug Development, Drug Targets, Easily Confused, Genetics, Mechanism of Action, Monoclonal Antibodies, Small Molecule Drugs

BLOOD CANCER: MULTIPLE MYELOMA Plasma cells are the antibody-producing cells of our immune system which happen to play a critical role in our defense against infections. In multiple myeloma, plasma cells begin to grow and divide in an uncontrolled manner, forming a cancerous mass known as a plasmacytoma. Marrow — which produces plasma — no longer functions in our defense, it simply takes … Read More

Nanobodies: These Are Not Your Mother’s mAbs

Emily BurkeBiologics, Biotech Basics, Cancer, Clinical Trials, Drug Development, Drug Targets, Mechanism of Action, Monoclonal Antibodies, Orphan Disease, Orphan Drugs

The Drug Kingpins Monoclonal antibodies (mAbs) are the undisputed drug kingpins. In 2013, the mAb market raked in $75 billion in combined sales, covering a whole range of indications from cancer and infectious disease, to autoimmune disorders, and even high cholesterol. Despite the success, mAbs have one chink in their armor: they cannot enter cells due to their large size, hampering their range … Read More

Putting The NA in DNA

Emily BurkeBiologics, Biotech Basics, Cancer, Cardiovascular Disease, Clinical Trials, Deoxyribonucleic Acid (DNA), Drug Development, Drug Targets, Mechanism of Action, Monoclonal Antibodies, Ribonucleic Acid (RNA), Small Molecule Drugs, The WEEKLY

Nucleic Acid Therapeutics Small molecule, peptide, and biologic drugs aren’t the only players in the game of drug development. A fourth class of therapeutics differs from all three of these: nucleic acid-based drugs. These drugs are rising in prominence due to their potential to specifically target a wide range of diseases, including various types of cancer, autoimmune, and infectious diseases. Companies … Read More

The Mechanics Of Melanoma

Emily BurkeBiologics, Biotech Basics, Cancer, Clinical Trials, Drug Development, Drug Targets, Mechanism of Action, Monoclonal Antibodies, Small Molecule Drugs, The WEEKLY

Spectrum Of Therapies Melanoma accounts for less than 1% of skin cancer cases yet causes the vast majority of skin cancer deaths. If detected early enough, melanoma is almost always curable. If not, its ability to metastasize makes it difficult to treat. Melanoma is more common in young adults than many other types of cancer, with 25% of new cases occurring in people under age … Read More

Therapeutic Antibody Primer

Emily BurkeBiologics, Biotech Basics, Cancer, Clinical Trials, Drug Development, Drug Targets, Easily Confused, Mechanism of Action, Monoclonal Antibodies, Small Molecule Drugs

Basics & Innovations Monoclonal antibody (mAb) therapeutics burst onto the healthcare scene 20 years ago, and today they remain one of the most versatile and effective therapeutics available. The tried and true mAbs are still in high demand, and we suspect this first wave of derivative products clamoring their way through the pipeline will be equally as successful. In this WEEKLY, we’ll … Read More

Harnessing Your Immune System For Good

Emily BurkeBiologics, Biotech Basics, Cancer, Drug Targets, Mechanism of Action, Monoclonal Antibodies

YOUR INNER IMMUNE WORKINGS What do monoclonal antibodies, CAR-T therapy, and checkpoint inhibitor treatments all have in common? They are immunotherapies, or therapies that activate the immune system to fight or prevent a disease. While an activated immune system can help save a life, an overactive immune system can attack the body it is charged with protecting. This over-activity is the … Read More

Unwiring The Biology Of Fibrosis

Emily BurkeAntisense, Biologics, Clinical Trials, Drug Development, Drug Targets, Mechanism of Action, Monoclonal Antibodies, Small Molecule Drugs, Term of the Week, The WEEKLY

Fibrotic Disease Innovations Fibrotic diseases — organ and tissue disorders that occur as a result of the buildup of excessive scar tissue — are sounding the alarm in the biotech sector. A silent epidemic creeping up on the Western world involves non-alcoholic steatohepatitis (NASH), or liver fibrosis associated with obesity and type 2 diabetes. Left untreated, NASH can lead to liver failure. Currently, … Read More

Killing Cancer At Its Stem Cell Origin

Emily BurkeBiologics, Cancer, Clinical Trials, Drug Development, Drug Targets, Mechanism of Action, Monoclonal Antibodies, Small Molecule Drugs

Killing Cancer When it comes to killing cancer, eradicating every single cell is the goal. But did you know there are different kinds of cancer cells? One specific type, called cancer stem cells (CSC), is catching the eye of drug developers. Discovered more than a decade ago, CSCs are hypothesized to be the drivers of cancer growth and metastasis. Let’s … Read More

Post-translational Modifications In Biotech

Emily BurkeBiologics, Biomanufacturing, Biotech Basics, Cancer, Deoxyribonucleic Acid (DNA), Drug Development, Drug Targets, Mechanism of Action, Monoclonal Antibodies

Basic Science Meets Application “Post-translational modification” may not be a term you hear every day, but it is critically important to the biotech industry—from understanding how cancer develops to producing biologics. Breaking the term down, we know that: “post” means “after.” “translation” is “the cellular process of making proteins.” “modification” means “change.” So, a post-translational modification (PTM) simply means that … Read More

A Bone To Pick With Osteoporosis

Emily BurkeBiologics, Clinical Trials, Drug Development, Drug Targets, Mechanism of Action, Monoclonal Antibodies

The Race To Be The Next Big Bone Drug Amgen’s recent positive Phase III results for an antibody drug is putting it neck and neck with Radius Health’s peptide — the latest in a batch of osteoporosis therapies edging their way to the market. The current widely prescribed generic — bisphosphonate — only works to slow the loss of bone, while these newer drugs add to the therapies that aim to rebuild. … Read More

The Tight Junction’s Function

Emily BurkeBiologics, Biotech Basics, Cancer, Clinical Trials, Drug Development, Drug Targets, Mechanism of Action, Monoclonal Antibodies, The WEEKLY

A Pathway Lies In The Bridge Between Cells Most of us remember from high school biology that cells are the basic building blocks of all living things. Cells join together to form tissues and organs such as hearts, lungs, and livers, which work together to create a functioning human. An adult human body contains trillions of cells, and these cells must … Read More

The Long And Short Of AMD

Emily BurkeBiologics, Clinical Trials, Deoxyribonucleic Acid (DNA), Drug Development, Drug Targets, Genetics, Mechanism of Action, Monoclonal Antibodies, Term of the Week, The WEEKLY

A Spotlight On One Of The Most Prevalent Eye Diseases It’s easy to take our ability to see for granted. On a day-to-day basis, we rely on vision to process information and to navigate the world without giving it a second thought. For the millions of people affected by eye disease, vision loss, and blindness, impaired vision is a daily reality … Read More

Breaking Bad With NSCLC & SCLC

Emily BurkeBiologics, Biotech Basics, Cancer, Clinical Trials, Cocktail Fodder, Drug Approvals, Drug Development, Drug Targets, Mechanism of Action, Monoclonal Antibodies, Small Molecule Drugs, The WEEKLY

BREAKING BAD The hit TV series Breaking Bad features anti-hero Walter White, who starts out as a sympathetic character: a mild-mannered high school chemistry teacher with a nagging cough that turns out to be lung cancer. Money problems precipitated by costly treatments, poor insurance, and a modest salary push him to start cooking up meth to ensure the financial security … Read More

Biotech In Space!

Emily BurkeBiologics, Drug Development, Drug Targets, Mechanism of Action, Monoclonal Antibodies, The WEEKLY

Experimenting In Lower Earth’s Orbit Drug discovery in space? If this sounds like a page from science fiction, think again. Leading pharmaceutical companies are now collaborating with NASA to run experiments on the International Space Station (ISS). The focus on bone density, protein structure, vaccine development, immune function, and aging brings a swath of potential to this fascinating endeavor. In … Read More

Without A Treg To Stand On

Emily BurkeBiologics, Cancer, Clinical Trials, Drug Development, Drug Targets, Mechanism of Action, Monoclonal Antibodies, Small Molecule Drugs, The WEEKLY

Regulatory T-Cells Make A Pathway After our focus on T-cell activated immunotherapies revving up the immune response, we turn to the other side of the coin—a subset of helper T-cells known as regulatory T-cells. Regulatory T-cells (Tregs) suppress the immune response.  The exact mechanism by which this suppression occurs is not entirely understood, but some of the effect is due … Read More

Next-Generation CAR-T

Emily BurkeBiologics, Business of Biotech, Cancer, Clinical Trials, Drug Development, Drug Targets, Genomics, Mechanism of Action, Monoclonal Antibodies, The WEEKLY

The Race Is On Our last WEEKLY—Hacking the Immune Response—unveiled the science behind CAR-T and TCR, two immunotherapies under the microscope of the mainstream press. The well-deserved media attention highlights the ability of these “living drugs” to recognize and obliterate cancers. With all of the early phase clinical success, a few challenges have popped up: • Safety: CAR-T and TCR can … Read More